Bocom International: Early Research Validation for Everest Med (01952) Could Drive Value Re-rating, Maintains "Buy" Rating

Stock News11-12

Bocom International has released a research report stating that Moderna and Merck's personalized mRNA cancer vaccine Intismeran achieved positive results in a Phase III melanoma study, providing clinical validation for this new treatment paradigm and highlighting the forward-looking positioning of Everest Med (01952) in this field. The firm maintains its "Buy" rating, bullish on the company's efficient BD and commercialization execution capabilities as well as continued progress in mRNA cancer vaccines and in vivo CAR-T.

Overseas Breakthrough Validates Technology Path, AI-Empowered mRNA/LNP Platform Supports Diversified Layout

The company has established an AI-empowered end-to-end mRNA platform with core advantages including: 1) AI-empowered molecular design: its proprietary AI algorithm "Miaosuan" is used to predict tumor neoantigens; the company also continuously optimizes codons, secondary structures, and UTR synergy, achieving protein expression levels nearly 5 times higher than early commercial systems; 2) Proprietary LNP delivery platform: the exclusive L41 mRNA LNP demonstrated superior anti-tumor efficacy in preclinical studies, and faster hepatic clearance of lipids is expected to reduce accumulation risks; 3) Full-process in-house manufacturing: the Jiashan facility supports personalized vaccine preparation within 6-8 weeks and is expected to continuously reduce costs and improve efficiency. Leveraging this platform, the company has comprehensively laid out personalized, off-the-shelf universal, and immunomodulatory cancer vaccines, with potential for combination therapy and sequential treatment; it is also developing in vivo CAR-T products, expanding into autoimmune and hematological tumor fields.

Early Clinical Signals Strengthen Confidence, Pipeline Advancement Expected to Bring Sustained Catalysts

The company's cancer vaccine has already demonstrated preliminary human activity: EVM16's Phase Ia IIT study results for advanced solid tumors were presented at AACR 2026, with 8 out of 9 patients showing T-cell responses in a dose-dependent trend; 1 confirmed partial response (PR) and 2 cases of stable disease (SD) were observed; preliminary safety and tolerability were favorable. Over the next year, the company will also see multiple catalysts: 1) Personalized cancer vaccine EVM16: submission of US/China IND (end of 2026/first half of 2027), Phase Ia Part 1 data readout (first half of 2027), Phase Ib first-line maintenance treatment partial data readout (second half of 2027); 2) Tumor-associated antigen vaccine EVM14: initiation of combination immunotherapy IIT enrollment (first half of 2027), US combination immunotherapy dose escalation data readout (second half of 2027); 3) Other pipelines: immunomodulatory cancer vaccine EVM15 (PDL1/IDO1) planned for US/China IND submission in the first half/second half of 2027; in vivo CAR-T product EVM18 is advancing US-China IND filing. Additionally, the firm believes attention should be paid to Moderna's subsequent exploration in more solid tumors and longer-term data in melanoma, which could further validate the potential of mRNA vaccines across tumor types and durability of benefit, serving as potential catalysts for re-rating the company's platform and pipeline value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment